02005.HK
SSY Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 2.70
−2.00%Year over year
Reported trailing growth
- Revenue
- -4.4%
- EBITDA
- -15.4%
- EBIT
- -25.1%
- EPS
- -23.0%
- Free cash flow
- +851.6%
- Operating cash flow
- +153.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -13.5%
- EBITDA
- -17.7%
- EBIT
- -23.8%
- Net income
- -25.2%
- EPS
- -25.0%
- Free cash flow
- -6.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026